DelveInsight’s analysis highlights the transformative impact of Novartis’ $1.4 billion acquisition of Tourmaline Bio (Nasdaq: TRML), announced on September 9, 2025. The deal underscores a paradigm shift toward anti-inflammatory strategies in treating atherosclerotic cardiovascular disease (ASCVD)—a progressive condition driven by systemic inflammation that affects millions...